Anlon Healthcare Ltd (AHCL) — shareholding pattern, promoter holding, financials and share price
About Anlon Healthcare Ltd (AHCL)
Anlon Healthcare Ltd operates in the Pharmaceuticals industry, within the Healthcare sector. It trades on the NSE as AHCL and on the BSE under scrip code 544497. Its ISIN is INE0Y8W01025.
Incorporated in 2013, Anlon Healthcare Limited is a chemical manufacturing company engaged in the manufacturing of Pharma Intermediates and active pharmaceutical ingredients (APIs). [1]
Anlon Healthcare manufactures pharmaceutical APIs and high‑purity intermediates from its Rajkot facility, provides custom manufacturing (CDMO) services, and has expanded via an IPO in August 2025; the company reports regulatory filings including 21 DMFs and commercial presence across 15 countries, positioning Anlon Healthcare as a research-driven API/intermediate manufacturer focused on regulated market customers.
The company reported a sharp year‑on‑year operational improvement: Q3 total income rose to INR 35.78 crore from INR 9.38 crore a year earlier, EBITDA of INR 12.54 crore at 35.1% margin and a return to PAT of INR 5.15 crore, reflecting stronger product mix, operating leverage and an expanding CDMO pipeline for Anlon Healthcare.
Listed peers in Pharmaceuticals: Kopran Ltd, Shree Ganesh Remedies Ltd, Hexagon Nutrition Ltd, Remus Pharmaceuticals Ltd, Sigachi Industries Ltd, Anuh Pharma Ltd.
Valuation & Returns
10 Jul 2026At ₹15.59 a share on 10 Jul 2026, Anlon Healthcare Ltd (AHCL) was valued at a price-to-earnings ratio of 29.8x against an industry P/E of 36.41x and a price-to-book of 10.3x on a book value of ₹1.51 per share as of Mar 2025. Solomo computes return on equity of 34.58% and return on capital employed of 32.51% from filed results. Earnings ratios use standalone results for the twelve months Jun 2025 to Mar 2026.
- P/E
- 29.8x
- Industry P/E
- 36.41x
- P/B
- 10.3x
- EPS (TTM)
- ₹0.52
- Book value / share
- ₹1.51
- ROE
- 34.58%
- ROCE
- 32.51%
- ROA
- 15.34%
- Debt / equity
- 0.73x
- Dividend yield
- 0%
- 52-week range
- ₹8.7 – ₹17.2
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Anlon Healthcare Ltd (AHCL) reported revenue of ₹172 crore, net profit of ₹29 crore and earnings per share of ₹0.54. That compares with revenue of ₹120 crore and net profit of ₹21 crore in Mar 2025. Figures are consolidated, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹51 crore and net profit ₹11 crore (consolidated).
| Metric | Mar 2025 | Mar 2026 |
|---|---|---|
| Revenue (₹ cr) | 120 | 172 |
| Net profit (₹ cr) | 21 | 29 |
| EPS (₹) | 0.51 | 0.54 |
| Measure | 3Y | 1Y |
|---|---|---|
| Sales growth | 27.95% | 80.67% |
| Profit growth | - | 112.42% |
Ownership Summary
Jun 2026As of Jun 2026, promoters hold 52.68% of Anlon Healthcare Ltd (AHCL) (unchanged from the previous quarter), foreign institutional investors (FII) hold 1.67% and domestic institutional investors (DII) hold 1.22%. Market capitalisation was ₹829 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Sep 2025.
Largest disclosed public shareholders in Jun 2026: SHREE DWARIKADHISH VENTURES LLP 7.53%, BAN LABS PRIVATE LIMITED 5.27%, LUV NATWARLAL UKANI 1.13%, HARSHAD RASIKLAL SHETH 1.13%, JAY MAULESHKUMAR UKANI 1.13%, HUF 1.04%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Jun 2026 | 52.68% | - | 1.67% | 1.22% | 47.32% |
| Mar 2026 | 52.68% | - | 0.32% | 4.6% | 47.32% |
| Dec 2025 | 52.68% | - | 0.23% | 4.49% | 47.32% |
| Sep 2025 | 52.68% | - | 0% | 2.83% | 47.32% |